Veradermics has successfully raised $256 million in an upsized IPO, reflecting strong investor interest in its oral minoxidil therapy for hair loss. The company's shares surged over 120% on their first trading day, indicating robust market confidence in its lead program, often referred to as 'oral Rogaine'.